Related Experiment Video
Updated: Aug 13, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
ZD-0892 AstraZeneca
1Nagoya University School of Medicine, Second Department of Internal Medicine, 86 Toki-Cho, Mizunami City, Gifu Prefecture, Japan. ohbayasi@nn.iij4u.or.jp
Abstract:
ZD-0892, a neutrophil elastase inhibitor, is under development by AstraZeneca as a potential treatment for chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD). It is in phase I clinical trials for these two indications [315489]. The compound was originally under investigation for the potential treatment of asthma, but development was discontinued for this indication [266604]. The compound is the follow-up to ZD-8321 (qv) [336599].
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Bioequivalence studies: Biowaivers
Pharmaceutical Equivalents
Drug Dosing: Obese Patients
Drug Dosing: Geriatric Patients

